Schedule of Segment Reporting Information, by Segment [Table Text Block] |
|
Year Ended October 31,
|
|
2019
|
|
2018
|
Net loss:
|
|
|
|
|
|
Cancer diagnostics
|
$
|
(5,196,471)
|
|
$
|
(5,920,457)
|
Cancer therapeutics
|
|
(5,752,318)
|
|
|
(7,073,322)
|
Patent licensing
|
|
(869,863)
|
|
|
(1,249,305)
|
Total
|
$
|
(11,818,652)
|
|
$
|
(14,243,084)
|
|
|
|
|
|
|
Total operating costs and expenses
|
$
|
12,140,005
|
|
$
|
15,401,558
|
Less non-cash share-based compensation
|
|
(5,713,746)
|
|
|
(8,895,614)
|
Operating costs and expenses excluding non-cash share-based compensation
|
$
|
6,426,259
|
|
$
|
6,505,944
|
|
|
|
|
|
|
Operating costs and expenses excluding non-cash
share based compensation expense:
|
|
|
|
|
|
Cancer diagnostics
|
$
|
2,689,761
|
|
$
|
2,431,810
|
Cancer therapeutics
|
|
2,670,482
|
|
|
2,120,614
|
Patent licensing
|
|
1,066,016
|
|
|
1,953,520
|
Total
|
$
|
6,426,259
|
|
$
|
6,505,944
|
|
October 31,
|
|
2019
|
|
2018
|
Total assets:
|
|
|
|
|
|
Cancer diagnostics
|
$
|
2,921,784
|
|
$
|
2,545,803
|
Cancer therapeutics
|
|
2,872,341
|
|
|
2,157,359
|
Patent licensing
|
|
499,568
|
|
|
1,745,380
|
Total
|
$
|
6,293,693
|
|
$
|
6,448,542
|
|